CN-122005656-A - Application of wild buckwheat rhizome freeze-dried powder in preparation of medicines for preventing or treating stibium pneumoconiosis

Abstract

The invention relates to the technical field of biological medicines, in particular to application of wild buckwheat rhizome freeze-dried powder in preparing a medicine for preventing or treating antimony pneumoconiosis. The mouse antimony pneumoconiosis model is constructed by pouring antimony (Sb) suspension into the trachea, and the wild buckwheat rhizome freeze-dried powder prepared by the invention can obviously relieve pulmonary fibrosis lesions caused by antimony exposure after being subjected to gastric lavage. The experiment result shows that H & E staining indicates that the lyophilized powder can obviously reduce the fibrosis severity of lung tissues, western Blot and PCR detection results indicate that the wild buckwheat can partially inhibit the expression of antimony-induced Col-1 and alpha-SMA at protein and gene levels, and in addition, the wild buckwheat can also obviously reduce the hydroxyproline content in lung tissues. The results show that the golden buckwheat rhizome freeze-dried powder can effectively improve a plurality of pathological indexes, reduce the pulmonary fibrosis degree, has good potential in preventing antimony pneumoconiosis, and has potential application value.

Inventors

• ZHAO XINYUAN
• JIANG MENGNA
• LI JINLONG
• ZHENG DONGNAN
• LI SHASHA
• Bu Wenxia
• CHENG DEMIN

Assignees

• 南通大学

Dates

Publication Date

20260512

Application Date

20260326

Claims (4)

1. 1. An application of rhizoma Fagopyri Dibotryis lyophilized powder in preparing medicine for preventing or treating stibium pneumoconiosis is provided.
2. 2. The use according to claim 1, wherein the medicament is for alleviating pulmonary fibrosis lesions caused by antimony exposure.
3. 3. The use according to claim 1 or 2, wherein the medicament is for reducing collagen deposition in lung tissue in an antimony exposure model group and/or for down regulating the expression levels of Col-1 and α -SMA proteins and genes in lung tissue.
4. 4. The use according to claim 1, wherein the medicament is for reducing the hydroxyproline content in lung tissue in an antimony exposure model group.

Description

Application of wild buckwheat rhizome freeze-dried powder in preparation of medicines for preventing or treating stibium pneumoconiosis Technical Field The invention relates to the technical field of biological medicines, in particular to application of wild buckwheat rhizome freeze-dried powder in preparing a medicine for preventing or treating antimony pneumoconiosis. Background Dust generated by metallic antimony (Sb) and its compounds during mining, smelting and processing operations can be inhaled through the respiratory tract and deposited in the lungs, and prolonged exposure can cause a occupational lung disease called antimony pneumoconiosis. The disease is mainly characterized by chronic pulmonary inflammation, progressive interstitial fibrosis, early pathological changes including alveolar macrophage massive infiltration, oxidative stress damage caused by Reactive Oxygen Species (ROS) outbreaks, and mitochondrial dysfunction. As the course of the disease progresses, continuous stimulation of antimony dust causes abnormal activation of pro-fibrotic factors such as transforming growth factor- β (TGF- β), which in turn promotes myofibroblast differentiation and excessive deposition of extracellular matrix, ultimately resulting in irreversible pathological changes represented by diffuse pulmonary interstitial fibrosis. Notably, antimony pneumoconiosis is often imaged with diffuse small nodular shadows accompanied by network changes, and pathologically it is seen that collagen fibers are wrapped around metal dust deposition sites, forming a characteristic fibrotic structure different from that of silicon nodules. There is a fundamental difference in differential diagnosis and treatment strategies between antimony pneumoconiosis and infectious pneumonia and other types of pulmonary fibrosis. Bacterial or viral pneumonia is usually caused by direct infection of pathogens, mainly neutrophil infiltration and exudative inflammation in alveolar spaces, most lesions are acute and reversible, and antibiotics or antiviral treatment can effectively control the conditions. Idiopathic Pulmonary Fibrosis (IPF) is of unknown etiology, and high-resolution CT is typically manifested as a predominantly subpleural latticed shadow and a honeycomb lung, pathologically characterized by fibroblast foci, and although anti-fibrotic therapy with either nidanib or pirfenidone is available, its drug response mechanism is different from that of metal dust. In contrast, antimony pneumoconiosis is driven by definite metal toxic substances, the fibrosis process of the antimony pneumoconiosis is closely related to continuous oxidative damage and mitochondrial dysfunction caused by antimony, specific therapeutic drugs aiming at the cause are not available at present, clinical treatment is mainly carried out by early inflammation and lung rehabilitation symptomatic treatment which are separated from an exposure environment and are interfered by glucocorticoid, and the curative effect of middle and late stages is very limited. In the aspect of traditional Chinese medicine application, wild buckwheat rhizome (Fagopyrum dibotrys (D. Don) Hara) is recorded by Chinese pharmacopoeia (2025 edition) and is used for treating pulmonary infectious diseases such as pulmonary abscess vomiting pus, pulmonary heat cough and the like, and has the main effects of clearing heat and detoxicating, expelling pus and removing blood stasis. No literature or patent has been found in the prior published studies suggesting its potential for intervention in pulmonary fibrosis due to metal dusting. Although Fagopyrum cymosum is known to contain flavonoids Cheng Fendeng as antioxidant active substances, whether it can be used to regulate antimony-induced mitochondrial dysfunction and specific fibrosis signaling pathways has not been supported by experimental evidence to date. From the theoretical analysis of traditional Chinese medicine, antimony pneumoconiosis can be classified as "Jinshi toxin hurting lung collaterals", and pathogenesis is that the pathogenic factor of Jinshi toxin stagnates lung collaterals, and qi consumption hurts yin, phlegm stasis stagnates to form mass. Fang Qiao can clear heat and dispel heat, but it is cool and purgation, so it is not suitable for treating syndrome of lingering pathogenic qi and accumulation of mass. Therefore, based on the existing cognition, the person skilled in the art lacks theoretical basis and experimental motivation for using wild buckwheat rhizome for preventing and treating antimony dust. In conclusion, the wild buckwheat rhizome extract is used for preventing or treating the antimony pneumoconiosis, belongs to the development of new application which is not suggested by any prior art, fills up the medicine blank in the field of preventing and treating the cause of the antimony pneumoconiosis, provides a new natural medicine selection for early intervention of antimony exposure people, and has remarkable innova